Warning Letter Roundup & Recap – October 13, 2015
This article was originally published in The Gray Sheet
Executive Summary
An FDA investigator observed two different products with the same lot number at a manufacturer of cannulas and trocars; employees at Lusys Labs – a maker of in vitro diagnostic kits – handled and packaged coated membranes with bare hands; procedures at software-maker Merge Healthcare allowed for devices that hadn't fully completed design validation to be shipped to end users for clinical use on patients; and more. Six device warning letters were listed by FDA this week.
You may also be interested in...
Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment
Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.
UK’s NICE Goes Ahead With Parkinson’s Product Funding But Pending Real-World Data
Five remote monitoring medical devices that have “transformational” potential for Parkinson’s disease are to be conditionally funded via the UK’s National Health Service in a drive to address clinical and cost-effectiveness uncertainties using data from real patients.
Expert Panel View On First Ebola Test Submission: Reservations About Use In EU
The IVD expert panel has reviewed the performance of the 16th IVD that it has been asked to assess. The outcome is generally favorable – but with some reservations, including its use in the EU.